Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

NCT02836795 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Urological Cancer

Interventions

BIOLOGICAL: humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)

Sponsor

Shanghai Junshi Bioscience Co., Ltd.